Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using base editing technology. The company designs therapies that aim to make targeted, single-base changes in DNA or RNA, with the goal of precisely correcting disease-causing mutations at the molecular level. Beam Therapeutics Inc. concentrates on serious conditions across areas such as hematology, liver and metabolic disorders, oncology, and genetic diseases, advancing a pipeline that includes programs like BEAM-101, BEAM-201, BEAM-301, and BEAM-302, as well as its ESCAPE platform for engineered stem cell therapies. Its business model centers on proprietary editing platforms, internal drug discovery, and strategic collaborations with larger pharmaceutical and biotechnology companies to co-develop or outlicense selected programs. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam Therapeutics Inc. plays a specialized role in the health technology and biotechnology sectors by providing tools and candidate therapies that support the broader shift toward highly targeted, mechanism-based treatments.